Can I read Phase 2 Trial of Temozolomide Plus Bevacizumab, Lithium, and Radiation Treatment for Newly Diagnosed High-Grade Gliomas: Interim Analysis on EtoBox?

Phase 2 Trial of Temozolomide Plus Bevacizumab, Lithium, and Radiation Treatment for Newly Diagnosed High-Grade Gliomas: Interim Analysis by M. Tam; M. Gruber; D. Gruber; J. Golfinos; E. Parker; D. Zagzag; A. Narayana is a Medicine article available to read on EtoBox.

What is Phase 2 Trial of Temozolomide Plus Bevacizumab, Lithium, and Radiation Treatment for Newly Diagnosed High-Grade Gliomas: Interim Analysis about?

registration, tumor (T) and affected lymph nodes (LNs) were contoured on CT, post gadolinium T1-weighted ultrafast gradient echo (VIBE), and ADC images for the purpose of comparing volumetric tumor regression and change of ADC signal with tumor response. Results: Mean absolute ADC values and relative ADC and volume changes during radiation therapy are shown in the Table . At the end of therapy, four of five patients had partial response, and one had stable disease according to RECIST 1.1. There was no significant difference in ADC increase and VIBE or CT volume reduction between responding and non-responding patients or between tumor cell types in this small group. ## Conclusions: The preliminary results of this study show ADC signal increases early during therapy. While volume reduction continues during therapy, ADC signal does not significantly change between the 30 Gy and 60 Gy time points. Further research needs to be undertaken to investigate the predictive value of ADC signal change for tumor response, local control, and as a basis for adaptive radiation therapy planning.

Who reads Phase 2 Trial of Temozolomide Plus Bevacizumab, Lithium, and Radiation Treatment for Newly Diagnosed High-Grade Gliomas: Interim Analysis?

Author

M. Tam; M. Gruber; D. Gruber; J. Golfinos; E. Parker; D. Zagzag; A. Narayana

Publisher

Elsevier BV

Published

2013

Language

EN

Field

Medicine (Health Sciences)